These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1512250)

  • 1. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
    Reilly CF; Hutzelmann JE
    J Biol Chem; 1992 Aug; 267(24):17128-35. PubMed ID: 1512250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
    Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
    Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA; Owensby DA; Sobel BE; Schwartz AL
    J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
    Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
    J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
    Reilly CF; Fujita T; Mayer EJ; Siegfried ME
    Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
    Carr ME; Krishnamurti C; Alving BM
    Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
    Masson C; Angles-Cano E
    Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
    Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
    Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activation of plasminogen by T-PA-PAI-1 complex in the absence of fibrin.
    Takada Y; Takada A
    Thromb Res; 1991 Jul; 63(1):169-77. PubMed ID: 1835180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
    Stringer HA; Pannekoek H
    J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
    Bu G; Morton PA; Schwartz AL
    J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
    Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Lawrence D; Strandberg L; Grundström T; Ny T
    Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
    J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro.
    Ramsby ML; Kreutzer DL
    Invest Ophthalmol Vis Sci; 1993 Oct; 34(11):3207-19. PubMed ID: 7691778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
    van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
    Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1.
    Gaussem P; Anglés-Cano E
    Biochim Biophys Acta; 1991 Sep; 1079(3):321-9. PubMed ID: 1911857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.